Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

2000-11-23

British Journal of Haematology , Volume 111 - Issue 1 p. 277- 279

Additional Metadata
Keywords	Acute myeloid leukaemia, Gemtuzumab ozogamicin (CMA-676)
Persistent URL	doi.org/10.1046/j.1365-2141.2000.02402.x, hdl.handle.net/1765/62302
Journal	British Journal of Haematology
Organisation	Department of Hematology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	de Vetten, M., Jansen, J., van der Reijden, B., Berger, M., Zijlmans, M., & Löwenberg, B. (2000). Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676). British Journal of Haematology, 111(1), 277–279. doi:10.1046/j.1365-2141.2000.02402.x

Publication